)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Corbus Pharmaceuticals Holdings (CRBP) investor relations material
Corbus Pharmaceuticals Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Focused on clinical-stage oncology and obesity therapeutics, with three main pipeline candidates: CRB-701, CRB-601, and CRB-913.
All three clinical programs are on track for data readouts in the second half of 2025.
CRB-701 received FDA Fast Track designation for relapsed or refractory metastatic cervical cancer.
Advanced clinical programs: CRB-701 Phase 1/2 dose escalation completed, dose optimization and combination studies ongoing; CRB-601 Phase 1 dose escalation underway; CRB-913 Phase 1 SAD/MAD dosing ongoing.
No product revenue; operations funded primarily through equity offerings and milestone payments.
Financial highlights
Net loss of $17.7 million for Q2 2025, compared to $10.0 million for Q2 2024; net loss of $34.6 million for the six months ended June 30, 2025, versus $16.9 million for the same period in 2024.
Operating expenses increased to $19.2 million in Q2 2025 from $11.0 million in Q2 2024, mainly due to higher clinical development costs.
Cash, cash equivalents, and investments totaled $116.6 million as of June 30, 2025, expected to fund operations through Q2 2027.
Working capital of $109.5 million at June 30, 2025.
Net loss per share was $1.44 for Q2 2025 and $2.83 for the six months ended June 30, 2025.
Outlook and guidance
Cash and investments expected to fund operations through Q2 2027 based on current plans.
Key clinical milestones expected in Q4 2025, including dose expansion data for CRB-701 and dose escalation data for CRB-601.
Phase 1b dose-range finding study for CRB-913 in obese non-diabetic individuals planned for Q4 2025.
Anticipates continued operating losses as clinical programs progress; additional capital will be required for further development.
CRB-701 combination arm strategy
CRB-913: How are CNS risks mitigated?
CRB-701: Next steps post-RP2D identification
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Corbus Pharmaceuticals Holdings earnings date
ESMO Congress 202519 Oct, 2025
Next Corbus Pharmaceuticals Holdings earnings date
ESMO Congress 202519 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company that specializes in precision oncology. The company's research and development efforts focus on innovative treatments that target well-understood biological pathways related to cancer. Corbus' pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) designed to target the Nectin-4 protein on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells. These treatments are intended to combat serious illnesses by offering new therapeutic options for patients. The company is headquartered in Norwood, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage